Kazia Therapeutics Annual Report 2021

52 Kazia Therapeutics Limited 52 Annual Report 2021 NOTE 9. CASH AND CASH EQUIVALENTS Consolidated 2021 2020 $ $ Current assets Cash at bank and on hand 21,086,760 1,264,044 Short-term deposits 6,500,000 7,500,000 27,586,760 8,764,044 NOTE 10. TRADE AND OTHER RECEIVABLES Consolidated 2021 2020 $ $ Current assets Trade receivables - 439 R&D tax rebate receivable - 1,017,278 - 1,017,717 Other receivables 76,675 177,125 Deposits held 7,687 566,508 Less: Provision for impairment of deposits held - (409,098) 84,362 1,352,252 Non-current assets Deposit paid 6,693,628 - 6,777,990 1,352,252 Of the deposit paid, $6.65m represents an advance to GCAR at the start of the GBM Agile trial, and is refundable if not utilised against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial, which is expected to be over 12 months from year end. NOTE 11. OTHER ASSETS Consolidated 2021 2020 $ $ Current assets Prepayments 1,719,696 537,305 NOTE 12. INTANGIBLES Consolidated 2021 2020 $ $ Non-current assets Licensing agreement – at acquired fair value 16,407,788 16,407,788 Less: Accumulated amortisation (5,081,993) (3,997,649) 11,325,795 12,410,139 Licensing agreement – at cost 10,857,763 - Less: Accumulated amortisation (180,965) - 10,676,798 - 22,002,593 12,410,139